India, June 4 -- Natera, Inc. (NTRA), a leader in cell-free DNA and precision medicine, announced that its genome-based Signatera MRD assay has secured Medicare coverage under LCD L38779.
This coverage includes Medicare beneficiaries with colorectal, breast, bladder, ovarian, lung cancers, and pan-cancer immunotherapy monitoring, aligning with prior coverage for Signatera.
The Medicare decision is supported by strong evidence validating the assay's accuracy, backed by over 100 clinical studies. At the 2025 ASCO Annual Meeting, Natera presented a pan-cancer study involving 392 patients and 2,600+ samples using Signatera Genome, a recently launched assay for clinical and research use. The test employs patented multiplex PCR-NGS technology f...